CANNDOC Pharma

Company Overview

Snapshot

Founded in January 2008, CANNDOC Pharma operates with 1–10 employees and was acquired by InterCure in September 2018. The company is known for its expertise in developing pharma-grade cannabis products, having provided over 500,000 doses to 15,000 patients.

Business overview

CANNDOC Pharma develops pharma-grade cannabis products, focusing on research, cultivation, processing, and product development under Good Manufacturing Practice (GMP) standards. The company's products are prescribed for various indications, including neuropathic pain, cancer-related pain, inflammatory bowel disease, post-traumatic stress disorder, Parkinson's disease, and epileptic seizures. Operating within the Health Tech & Life Sciences sector, specifically Medical Cannabis, CANNDOC Pharma serves markets in Israel, Canada, and Europe.

Strategic signal

In September 2025, CANNDOC Pharma acquired Botanico, signaling an expansion of its market reach and product portfolio within the cannabis industry. This acquisition demonstrates the company's strategic intent to grow through inorganic means, potentially leveraging Botanico's assets to enhance its position in the medical cannabis market.

Company Intelligence Q&A

When was CANNDOC Pharma acquired?

CANNDOC Pharma was acquired by InterCure in September 2018.

What significant acquisition did CANNDOC Pharma make recently?

In September 2025, CANNDOC Pharma acquired Botanico, expanding its access to the US cannabis market.

What was a key partnership for CANNDOC Pharma in early 2020?

In March 2020, CANNDOC Pharma and Super-Pharm signed a long-term partnership agreement.

What strategic alliance did CANNDOC Pharma's owner, InterCure, form in late 2020?

In December 2020, Charlotte's Web expanded into Israel through a strategic alliance with InterCure, owner of CANNDOC Pharma.

What was the nature of the agreement between Organigram and CANNDOC Pharma in mid-2020?

In June 2020, Organigram and CANNDOC Pharma signed an international strategic agreement.